期刊
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
卷 4, 期 9, 页码 1223-1234出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.4.9.1223
关键词
antidepressant; anxiety disorder; bipolar disorder; depression; glutamate; mania; plasticity; psychiatry; riluzole; treatment
资金
- Intramural NIH HHS [Z01 MH002828-05, Z01 MH002857-03] Funding Source: Medline
- NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002828, Z01MH002857] Funding Source: NIH RePORTER
Background: The glutamate system seems to be an important contributor to the pathophysiology of mood and anxiety disorders. Thus, glutamatergic modulators are reasonable candidate drugs to test in patients with mood and anxiety disorders. Riluzole, a neuroprotective agent with anticonvulsant properties approved for the treatment of amyotrophic lateral sclerosis (ALS) is one such agent. Objective: To assess the potential risks and benefits of riluzole treatment in psychiatric patients. Methods: A PubMed search was performed using the keywords 'riluzole', 'inhibitor of glutamate release' and 'glutamatergic modulator' to identify all clinical studies and case reports involving riluzole in psychiatric patients. Results/conclusion: Riluzole's side effect profile is favorable and preliminary results regarding riluzole for the treatment of severe mood, anxiety and impulsive disorders are encouraging.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据